Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:TARO
- CUSIP: N/A
- Web: www.taro.com
Capitalization:- Market Cap: $4.29114 billion
- Outstanding Shares: 40,489,000
Average Prices:- 50 Day Moving Avg: $105.17
- 200 Day Moving Avg: $111.63
- 52 Week Range: $92.28 - $124.52
P/E:- Trailing P/E Ratio: 10.79
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $806.92 million
- Price / Sales: 5.33
- Book Value: $52.84 per share
- Price / Book: 2.01
Profitability:- EBIDTA: $465.05 million
- Net Margins: 49.69%
- Return on Equity: 19.71%
- Return on Assets: 17.74%
Debt:- Current Ratio: 9.40%
- Quick Ratio: 8.70%
Misc:- Average Volume: 102,992 shs.
- Beta: 0.65
- Short Ratio: 22.83
Frequently Asked Questions for Taro Pharmaceutical Industries (NYSE:TARO)
What is Taro Pharmaceutical Industries' stock symbol?
Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."
How were Taro Pharmaceutical Industries' earnings last quarter?
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Monday, May, 22nd. The company reported $2.05 earnings per share for the quarter. The company earned $196.41 million during the quarter. Taro Pharmaceutical Industries had a net margin of 49.69% and a return on equity of 19.71%. View Taro Pharmaceutical Industries' Earnings History.
When will Taro Pharmaceutical Industries make its next earnings announcement?
Who are some of Taro Pharmaceutical Industries' key competitors?
Some companies that are related to Taro Pharmaceutical Industries include Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Catalent (CTLT), Valeant Pharmaceuticals International (VRX), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), AKCEA THERAPEUT (AKCA), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA) and Pacira Pharmaceuticals (PCRX).
Who are Taro Pharmaceutical Industries' key executives?
Taro Pharmaceutical Industries' management team includes the folowing people:
- Dilip Shantilal Shanghvi, Chairman of the Board
- Uday Baldota, Chief Executive Officer, Director
- Abhay Gandhi, Vice Chairman of the Board
- Mariano Balaguer, Chief Financial Officer, Chief Accounting Officer, Vice President
- Stephen Manzano Esq., Group Vice President, General Counsel, Secretary, Corporate Compliance
- Itamar Karsenti, Vice President - Head of Operations, Haifa
- Chantal LeBlanc, Vice President - Global Quality
- Daryl LeSueur, Vice President - Head of Operations, Brampton, Canada
- Michael Perfetto, Group Vice President and Chief Commercial Officer of the Generic Rx and OTC Business
- Michael Teiler, Group Vice President - Portfolio Management
Who owns Taro Pharmaceutical Industries stock?
Taro Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional investors include Matthews International Capital Management LLC (1.99%), Schroder Investment Management Group (1.68%), FMR LLC (1.15%), Renaissance Technologies LLC (0.67%), APG Asset Management N.V. (0.55%) and State Street Corp (0.51%). View Institutional Ownership Trends for Taro Pharmaceutical Industries.
Who sold Taro Pharmaceutical Industries stock? Who is selling Taro Pharmaceutical Industries stock?
Taro Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Schroder Investment Management Group, Renaissance Technologies LLC, Virginia Retirement Systems ET AL, Carmignac Gestion, Northern Trust Corp, Andra AP fonden and Korea Investment CORP. View Insider Buying and Selling for Taro Pharmaceutical Industries.
Who bought Taro Pharmaceutical Industries stock? Who is buying Taro Pharmaceutical Industries stock?
Taro Pharmaceutical Industries' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Dimensional Fund Advisors LP, River Road Asset Management LLC, Aperio Group LLC, AHL Partners LLP, Acadian Asset Management LLC, Citadel Advisors LLC and Clinton Group Inc.. View Insider Buying and Selling for Taro Pharmaceutical Industries.
How do I buy Taro Pharmaceutical Industries stock?
Shares of Taro Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Taro Pharmaceutical Industries' stock price today?
One share of Taro Pharmaceutical Industries stock can currently be purchased for approximately $106.16.
MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Taro Pharmaceutical Industries (NYSE:TARO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Taro Pharmaceutical Industries (NYSE:TARO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/23/2017 | Credit Suisse Group | Downgrade | Outperform -> Neutral | | Low |  |
(Data available from 9/20/2015 forward)
Earnings History for Taro Pharmaceutical Industries (NYSE:TARO)Earnings History by Quarter for Taro Pharmaceutical Industries (NYSE TARO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | N/A | |
| 5/22/2017 | Q4 | | $2.05 | | $196.41 million | View | N/A | |
| 8/10/2016 | Q1 | | $2.59 | $215.30 million | $233.80 million | View | N/A | |
| 5/26/2016 | Q4 | | $2.68 | | $265.07 million | View | Listen | |
| 2/10/2016 | Q316 | | $4.41 | $974.38 million | $258.30 million | View | N/A | |
| 8/6/2015 | Q116 | | $2.42 | $1.01 billion | $215.30 million | View | N/A | |
| 5/26/2015 | Q415 | | $3.56 | $881.79 million | $244.18 million | View | Listen | |
| 2/10/2015 | Q315 | | $3.33 | $213.60 million | $237.70 million | View | N/A | |
| 5/27/2014 | Q4 | $5.93 | $2.10 | $165.13 million | $187.20 million | View | N/A | |
| 2/10/2014 | Q214 | | $2.59 | $185.70 million | $213.60 million | View | N/A | |
| 11/12/2013 | Q3 | | $2.15 | | | View | N/A | |
| 8/7/2013 | Q114 | | $1.32 | $159.15 million | $153.20 million | View | N/A | |
| 5/23/2013 | Q4 2013 | | $1.10 | $145.00 million | $165.10 million | View | N/A | |
| 11/1/2012 | Q213 | | $1.46 | $138.25 million | $160.97 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Taro Pharmaceutical Industries (NYSE:TARO)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Taro Pharmaceutical Industries (NYSE:TARO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Taro Pharmaceutical Industries (NYSE:TARO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Taro Pharmaceutical Industries (NYSE:TARO)
Latest Headlines for Taro Pharmaceutical Industries (NYSE:TARO)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 9:37 AM |
| Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 10:58 AM |
 | Taro Pharmaceutical Industries Ltd. (TARO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - September 9 at 4:16 PM |
| Taro Announces Joining of CEO
finance.yahoo.com - September 2 at 9:18 AM |
| Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : August 21, 2017
finance.yahoo.com - August 23 at 12:19 PM |
| Zacks: Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - August 18 at 8:36 PM |
| See what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.
finance.yahoo.com - August 13 at 6:41 AM |
| Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 11 at 8:42 PM |
| Taro Pharmaceutical Industries Ltd. (TARO) Downgraded by TheStreet to C+
www.americanbankingnews.com - August 11 at 3:24 PM |
| Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : August 9, 2017
finance.yahoo.com - August 10 at 8:33 AM |
| IHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 10 at 8:33 AM |
| Taro Provides Results for Quarter Ended June 2017
finance.yahoo.com - August 9 at 8:02 AM |
| Taro posts 1Q profit
finance.yahoo.com - August 9 at 8:02 AM |
 | Taro Pharmaceutical: Solid Cash-Rich Business With No Debt And A Catalyst
seekingalpha.com - August 5 at 7:34 AM |
| Taro to Announce First Quarter Results on August 8, 2017
finance.yahoo.com - August 3 at 7:47 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Given Average Rating of "" by Brokerages
www.americanbankingnews.com - August 2 at 10:30 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:31 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - July 30 at 10:42 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Lifted to B- at TheStreet
www.americanbankingnews.com - July 23 at 9:26 PM |
| Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Downgraded by BidaskClub
www.americanbankingnews.com - July 16 at 9:32 PM |
| Contrasting Amphastar Pharmaceuticals (AMPH) & Taro Pharmaceutical Industries (TARO)
www.americanbankingnews.com - July 15 at 10:04 PM |
| [$$] In Hot Pursuit of Indian Growth Stocks
finance.yahoo.com - July 14 at 8:56 AM |
| ETFs with exposure to Taro Pharmaceutical Industries Ltd. : July 12, 2017
finance.yahoo.com - July 13 at 10:14 AM |
| ETFs with exposure to Taro Pharmaceutical Industries Ltd. : June 27, 2017
finance.yahoo.com - June 27 at 8:13 PM |
| Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q4, 2017 By the Numbers : June 26, 2017
finance.yahoo.com - June 27 at 8:53 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - June 24 at 3:38 PM |
| Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : June 21, 2017
finance.yahoo.com - June 22 at 2:00 PM |
| Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017
finance.yahoo.com - June 22 at 2:00 PM |
| TheStreet Lowers Taro Pharmaceutical Industries Ltd. (TARO) to C
www.americanbankingnews.com - June 18 at 11:28 PM |
| BidAskClub Lowers Taro Pharmaceutical Industries Ltd. (TARO) to Sell
www.americanbankingnews.com - June 10 at 12:02 AM |
 | Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
www.bloomberg.com - May 27 at 6:09 AM |
 | Oversold Conditions For Taro Pharmaceutical Industries (TARO)
www.nasdaq.com - May 25 at 4:05 AM |
| Edited Transcript of TARO earnings conference call or presentation 23-May-17 12:00pm GMT
finance.yahoo.com - May 25 at 4:05 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Stock Rating Lowered by Credit Suisse Group AG
www.americanbankingnews.com - May 23 at 11:16 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 23 at 9:27 AM |
| Taro Provides Results for Year Ended March 31, 2017
finance.yahoo.com - May 22 at 7:07 PM |
| Taro posts 4Q profit
finance.yahoo.com - May 22 at 7:07 PM |
 | Crescita Therapeutics™ Announces 2017 First Quarter Results
www.streetinsider.com - May 16 at 8:49 AM |
| Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : May 15, 2017
finance.yahoo.com - May 15 at 7:22 PM |
| Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017
finance.yahoo.com - May 15 at 7:22 PM |
| Taro Pharmaceutical Industries (TARO) Receiving Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 5 at 10:56 PM |
| Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : May 4, 2017
finance.yahoo.com - May 4 at 10:31 AM |
| Taro Pharmaceutical Industries (TARO) Earning Very Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 2:56 PM |
| Taro Pharmaceutical Industries (TARO) Receives News Sentiment Score of 0.10
www.americanbankingnews.com - April 26 at 12:34 PM |
| Crescita Therapeutics Enters Agreement with Taro Pharmaceuticals (TARO) for Pliaglis
www.streetinsider.com - April 26 at 8:54 AM |
| Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : April 25, 2017
finance.yahoo.com - April 25 at 7:07 PM |
| Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : April 24, 2017
finance.yahoo.com - April 24 at 10:46 AM |
| Taro Pharmaceutical Industries (TARO) Earning Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 22 at 8:31 AM |
| Taro Pharmaceutical Industries (TARO) Receives Daily Media Sentiment Score of 0.50
www.americanbankingnews.com - April 18 at 11:30 AM |
| Taro Pharmaceutical Industries Ltd. (TARO) Raised to B at TheStreet
www.americanbankingnews.com - April 17 at 12:52 AM |
Taro Pharmaceutical Industries (TARO) Chart for Wednesday, September, 20, 2017
